Azithromycin Safety Announcement – In a Safety Announcement dated August 3, 2018, The U.S. Food and Drug Administration (FDA) warned that the antibiotic azithromycin (Zithromax, Zmax) should not be given long-term to prevent a certain inflammatory lung condition in patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant. The announcement was made after results of a clinical trial found an increased rate of relapse in cancers affecting the blood and lymph nodes, including death, in these patients. The FDA is reviewing additional clinical data regarding this matter, and will communicate their findings and recommendations when the review is complete.
Azithromycin Manufacturer Issues “Dear Healthcare Provider Letter”
The FDA Safety Announcement stated: “The serious lung condition for which long-term azithromycin was being studied called bronchiolitis obliterans syndrome is caused by inflammation and scarring in the airways of the lungs, resulting in severe shortness of breath and dry cough. Cancer patients who undergo stem cell transplants from donors are at risk for bronchiolitis obliterans syndrome. The manufacturer of brand name azithromycin is providing a Dear Healthcare Provider letter on this safety issue to health care professionals who care for patients undergoing donor stem cell transplants.
Azithromycin is not approved for preventing bronchiolitis obliterans syndrome. It is an FDA-approved antibiotic used to treat many types of infections affecting the lungs, sinuses, skin, and other parts of the body. The drug has been used for more than 26 years. It is sold under the brand names Zithromax and Zmax and as generics by many different drug companies. It works by stopping the growth of bacteria that can cause infections.
There are no known effective antibiotic treatments for prophylaxis of bronchiolitis obliterans syndrome. Health care professionals should not prescribe long-term azithromycin for prophylaxis of bronchiolitis obliterans syndrome to patients who undergo donor stem cell transplants because of the increased potential for cancer relapse and death.”
FDA Advice for Stem Cell Transplant Patients Who Are Taking Azithromycin
The FDA cautioned stem cell transplant patients to not stop taking their axithromycin without taking to their doctor stating “Patients who have had a stem cell transplant should not stop taking azithromycin without first consulting with your health care professional. Doing so could be harmful without your health care professional’s direct supervision. Talk with them if you have any questions or concerns about taking this medicine.”
French Clinical Research Findings Identify Increased Risk
The increased risk of cancer relapse and death was observed by French researchers conducting a clinical trial investigating the effectiveness of long-term azithromycin to prevent bronchiolitis obliterans syndrome in patients who undergo donor, or allogenic, stem cell transplants for cancers of the blood and lymph nodes. According to the FDA, the researchers concluded that “the risks of long-term azithromycin exposure after donor stem cell transplantation may exceed the benefits” however, the clinical trial “could not determine why the rates of cancer relapse and death were higher with azithromycin.”
The clinical trial referred to as “ALLOZITHRO” was stopped approximately 13 months after 480 patients were enrolled due to the unexpected increase in the rate of both cancer relapses and death observed in patients taking azithromycin. The FDA reported that “Cancer relapse was observed in 77 patients (32.9%) with azithromycin treatment compared to 48 patients (20.8%) with placebo, which is an inactive treatment. A total of 95 patients died in the azithromycin treatment group versus 66 patients in the placebo group; thus, the 2-year survival rate was 56.6% in azithromycin-treated patients compared to 70.1% in those receiving a placebo. In the first few months of the trial, the death rate was about equal between those receiving azithromycin and placebo. However, an imbalance occurred subsequently and continued until the 2-year time point when the study was stopped.”
FDA Urges Healthcare Providers and Consumers to Report Drug Safety Information
The FDA urges health care professionals and patients to report side effects involving azithromycin and other drugs to the FDA MedWatch program at FDA Drug Safety Reporting.
Contact The Weinberg Law Firm for Product Liability Lawsuit Information
Since 1984, New Brunswick NJ Attorney Eric Weinberg, has assisted those injured by defective medical drugs and devices. Please call our law firm toll free at 877-934-6274 for a free, non- obligatory legal case evaluation. You can also contact our firm by using the easy-to-use case evaluation form found on this page.
Please see C diff Lawsuit and Blood Clot Lawsuit to learn more about our legal services.
